Maciej Wieczorek

Maciej Wieczorek

Auto-generated profile, based on publicly available information

Maciej Wieczorek

Celon Pharma S.A., Research and Development Center, 15 Marymoncka, 05-152 Kazuń Nowy, Poland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AKAgnieszka Klusek
Agnieszka Klusek
KAKamil Adasiewicz
Kamil Adasiewicz
ABAndżelika Bystrzejewska
Andżelika Bystrzejewska
PRPiotr J. Rudzki
Piotr J. Rudzki
MWMaciej Wieczorek
Maciej Wieczorek
EJEwelina Juszczyk
Ewelina Juszczyk
Accurate measurement of messenger RNA (mRNA) concentration and encapsulation efficiency remains a challenging task during mRNA-lipid nanoparticle (LNP) formulation development and quality control. RiboGreen-based fluorescence assays are often used for this purpose. LNP formulations are colloidal systems and may exhibit turbidity, which can interfere with fluorescence detection. The impact of LNP-related optical properties on assay performance remains insufficiently characterized. This study aimed to evaluate whether and how physicochemical factors associated with LNP-based drug-delivery systems influence fluorometric mRNA quantification. Empty LNPs, with the same lipid composition as mRNA-loaded LNPs, were used as a model matrix causing turbidity. Their effect on the RiboGreen fluorescence signal was assessed following dilution and then in different scenarios in the presence of free and encapsulated mRNA. The UV–Vis spectrum of the placebo dispersion was recorded to examine possible optical interference in the measurement range. We quantitatively characterized the suppression of fluorescence signals in the presence of LNPs in a concentration-dependent manner. These findings indicate that turbidity and LNP-associated matrix effects can bias RiboGreen-based mRNA quantification. To ensure reliable determination of mRNA concentration and accurate calculation of encapsulation efficiency in LNP formulations, method-specific dilution factors should be applied.

12 September 2022 in Biuletyn Historii Sztuki
Verified
Journal Article
Open access
PDF file
MWMaciej Wieczorek
Maciej Wieczorek
Artykuł podejmuje temat dekorowanych ksiąg należących do zespołu Metryki Koronnej ze zbiorów Archiwum Głównego Akt Dawnych w Warszawie. Zdobienia zidentyfikowano na kartach 31 woluminów powstałych w XVII i XVIII w. Analiza zgromadzonego materiału wykazała pokrewieństwa łączące dekorowane księgi regestru z iluminacjami dokumentów wydawanych przez polskich monarchów. Oprócz analogii kompozycyjnych odnotować można także udział tych samych twórców. Na kartach woluminów udało się zidentyfikować dzieła artystów opisywanych we wcześniejszej literaturze (Ludwika Dagoberta, Wojciecha Domańskiego), a także dekoratorów dotychczas nienotowanych (Jana Raweckiego, Jakuba Czechowicza). Zaobserwowano również, że większość autorów zdobień rekrutowała się z personelu kancelarii królewskiej. Dekoracje ksiąg Metryki Koronnej mogą zatem stanowić cenne źródło informacji dla badań nad składem osobowym centralnych urzędów państwa.

31 July 2026 in CNS Drugs
Verified
Journal Article
Open access
PDF file
MWMaciej Wieczorek
Maciej Wieczorek
Napoleon WaszkiewiczNapoleon Waszkiewicz
Napoleon Waszkiewicz
EGEwa Gromniak-Haniecka
Ewa Gromniak-Haniecka
JRJános Miklós Réthelyi
János Miklós Réthelyi
MPMykhaylo Pustovoyt
Mykhaylo Pustovoyt
JSJoanna Sierzputowska-Prarat
Joanna Sierzputowska-Prarat
Background Drugs that inhibit phosphodiesterase 10A (PDE10A) activity have shown efficacy in animal models. However, clinical trials of PDE10A inhibitors in patients with schizophrenia have failed to provide clinically significant results up to this point. Our study investigated whether alofropodect (previously referred to as CPL’36 or CPL500036), a PDE10A inhibitor with an improved pharmacological profile compared with other PDE10A inhibitors, including a fast dissociation rate and high activity, could improve symptoms of acute schizophrenia. Methods In this phase 2, randomised, double-blind, placebo-controlled, parallel-group trial (11 centres, three countries), investigators randomly assigned hospitalised patients with acute schizophrenia to treatment or placebo groups. The main inclusion criteria were age 18–65 years, a documented diagnosis of schizophrenia for at least 2 years before screening and a positive and negative syndrome scale (PANSS) total score ≥ 80. Participants were randomly assigned (1:1:1) to receive oral alofropodect (20 mg or 40 mg) or placebo administered once daily in the morning for 4 weeks. The primary endpoint of the study was an improvement in the PANSS positive subscale at week 4. The secondary endpoints included improvements in PANSS total and negative subscale scores, along with other efficacy and safety assessments. Clinical responders were defined as those with a ≥ 30% reduction in PANSS total score from baseline at week 4. Results Between 24 May 2021 and 8 May 2024, investigators randomised 189 patients into three groups: 58 into the alofropodect 20 mg group, 66 into the alofropodect 40 mg group and 65 into the placebo group. The mean age was 41.7 years (standard deviation (SD) 10.1), and 119 (63%) participants were men, 70 (37%) were women. All participants were White. We measured the difference in PANSS positive subscale before and after treatment, and the change met the primary endpoints at week 4 with the group where alofropodect 20 mg was compared with placebo (− 3.70 [90% CI − 5.51 to − 1.89]; p < 0.001) and alofropodect 40 mg versus placebo (− 6.35 [90% CI − 8.12 to − 4.57]; p = 0.001). Both the 20-mg and 40-mg doses of alofropodect were effective in improving the total PANSS score compared with placebo and met most secondary efficacy endpoints. A clinical response was observed in 2 of 53 patients (3.8%) in the placebo group, 8 of 52 patients (15.4%) in the 20 mg group and 22 of 52 patients (42.3%) in the 40 mg group at week 4. The compound was well tolerated, with only a few serious adverse events. The discontinuation rates were similar in the placebo and treatment arms. Extrapyramidal symptoms (EPS) occurred only in the active treatment groups, but rates were low overall. Somnolence was also reported only in alofropodect groups. Vital signs and biochemical parameters remained unaffected by either dose at any time point. Specifically, blood glucose, total cholesterol and triglycerides did not increase at any dose compared with placebo within our study window. Conclusions Alofropodect was effective in the treatment of acute schizophrenia symptoms and was well-tolerated, warranting further investigation in larger clinical studies. Clinical Trial Registration Clinicaltrials.gov identifier: NCT05278156; registration date: 2022-02-09.

31 July 2026 in Acta Poloniae Pharmaceutica - Drug Research
Verified
Journal Article
Open access
JKJakub Dariusz Kałdowski
Jakub Dariusz Kałdowski
MJMartyna Jaworska
Martyna Jaworska
MLMichał Adam Laszczyk
Michał Adam Laszczyk
MGMichał Górka
Michał Górka
MWMaciej Wieczorek
Maciej Wieczorek
A simple HPLC-UV method was developed and validated for the determination of formaldehyde in propylene glycol after derivatization with Nash reagent. Optimized off-line derivatization was followed by reversed-phase separation with ammonium bicarbonate buffer and acetonitrile, and detection of the formaldehyde derivative at 410 nm wavelength. The selected mobile phases were compatible with LC-MS, which enabled to confirm the identity of the derivative formed during the reaction. The method was validated according to ICH Q2(R2) and showed satisfactory specificity, linearity, precision, accuracy, and sensitivity. The LOD and LOQ were 0.0095 and 0.0317 µg/mL, respectively. Repeatability and intermediate precision were confirmed with RSD values not exceeding 0.52%, while recoveries ranged from 99.22% to 100.34%. The method was successfully applied to the determination of trace formaldehyde in a propylene glycol sample. Owing to its short run time, simple sample preparation, and use of standard HPLC-UV equipment, the procedure is suitable for routine quality control applications.